<DOC>
	<DOCNO>NCT00430885</DOCNO>
	<brief_summary>The instigator hypothesize IVIG , give acute phase follow MI patient risk develop HF , improve cardiac performance , attenuate cardiac remodel phase , therapy prevent development chronic HF result long term beneficial effect also therapy stop .</brief_summary>
	<brief_title>Effect Intravenous Immunglobulin ( IVIG ) After Myocardial Infarction</brief_title>
	<detailed_description>This double-blind placebo-controlled study represent new approach cardiovascular disease . The project deal unresolved issue intersection cardiology , immunology molecular biology . IVIG/placebo give induction therapy 5 day thereafter monthly infusion 5 month . Change leave ventricular remodel assessed baseline , 6 12 month MRI echocardiography . The objective : 1 . The primary objective study evaluate effect IVIG LV remodel function : LV remodel evaluate magnetic resonance imaging ( MRI ) offer unsurpassed precision measurement heart volumes function . End point LV-end systolic diastolic volume ( LVESV , LVEDV ) , regional wall motion score index ( WMSI ) , LV-ejection fraction ( LV-EF ) . 2 . The secondary objective study evaluate effect IVIG myocardial marker B-Type Natriuretic Peptide ( BNP ) . BNP sensitive marker degree HF besides prognostic indicator 18-20 . 3 . The tertiary objective study evaluate effect IVIG : . Quality life . b . Effect New York Heart Association ( NYHA ) functional class . c. Effect immunological variable . . Inflammatory cytokine TNF-alpha , IL-6 , IL-18 . ii . Anti-inflammatory cytokine IL-10 transform growth factor beta iii . Chemokines monocyte chemoattractant protein 1 , IL-8 CCL21 . iv . Regulators hypertrophy matrix metalloproteinases , endogenous inhibitor ( i.e. , TIMPs ) procollagen III N-terminal . d. Effect neurohormone . e. Withdrawals . f. Side effect .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Age 1880 year Have recent MI ( &lt; 5days ) Have ASAT &gt; 100 U/L CKMB &gt; 50 U/L . Have LVEF &lt; 40 % . Are optimal medical treatment consider unsuitable surgical intervention . Evidence unstable disease , concomitant ischemia unstable angina hospitalization . Significant concomitant disease infection , pulmonary disease connective tissue disease . Participating study . Inability participate . Diseases require surgery . Planned revascularisation . Known hypersensitivity IVIG .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Myocardial infarction</keyword>
	<keyword>Patients acute myocardial infarction</keyword>
</DOC>